Stockreport

Enanta Announces Positive Results of ARGON-1 Study of its lead FXR Agonist, EDP-305, for the Treatment of NASH

Enanta Pharmaceuticals, Inc.  (ENTA) 
Last enanta pharmaceuticals, inc. earnings: 2/6 04:00 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.enanta.com/investor-overview
PDF Primary endpoint, ALT reduction at week 12, was met in the 2.5mg dosing groupKey secondary endpoint, reduction in liver fat content as measured by MRI-PDFF at week 12, w [Read more]